APL
MCID: ACT119
MIFTS: 63

Acute Promyelocytic Leukemia (APL)

Categories: Blood diseases, Cancer diseases, Genetic diseases, Rare diseases

Aliases & Classifications for Acute Promyelocytic Leukemia

MalaCards integrated aliases for Acute Promyelocytic Leukemia:

Name: Acute Promyelocytic Leukemia 56 12 74 52 25 58 29 6 15 17 71
Acute Myeloblastic Leukemia Type 3 12 74 52
Leukemia, Acute Promyelocytic 56 25 13
Aml M3 52 25 58
Acute Myeloid Leukemia with T(15;17)(q22;q12);(pml/raralpha) and Variants 52 58
Aml with T(15;17)(q22;q12);(pml/raralpha) and Variants 52 58
Leukemia, Acute Promyelocytic, Somatic 56 39
Acute Myeloblastic Leukemia 3 52 58
Apml 52 58
Apl 56 25
Leukemia, Promyelocytic, Acute 43
Leukemia, Acute, Promyelocytic 39
Leukemia Promyelocytic Acute 54
Myeloid Leukemia, Acute, M3 25
Acute Myeloid Leukemia M3 12
M3 Anll 25

Characteristics:

Orphanet epidemiological data:

58
acute promyelocytic leukemia
Prevalence: 1-9/1000000 (United States),1-9/1000000 (Europe),1-9/1000000 (France); Age of onset: Adult; Age of death: elderly;

HPO:

31
acute promyelocytic leukemia:
Inheritance somatic mutation


Classifications:

Orphanet: 58  
Rare haematological diseases


Summaries for Acute Promyelocytic Leukemia

Genetics Home Reference : 25 Acute promyelocytic leukemia is a form of acute myeloid leukemia, a cancer of the blood-forming tissue (bone marrow). In normal bone marrow, hematopoietic stem cells produce red blood cells (erythrocytes) that carry oxygen, white blood cells (leukocytes) that protect the body from infection, and platelets (thrombocytes) that are involved in blood clotting. In acute promyelocytic leukemia, immature white blood cells called promyelocytes accumulate in the bone marrow. The overgrowth of promyelocytes leads to a shortage of normal white and red blood cells and platelets in the body, which causes many of the signs and symptoms of the condition. People with acute promyelocytic leukemia are especially susceptible to developing bruises, small red dots under the skin (petechiae), nosebleeds, bleeding from the gums, blood in the urine (hematuria), or excessive menstrual bleeding. The abnormal bleeding and bruising occur in part because of the low number of platelets in the blood (thrombocytopenia) and also because the cancerous cells release substances that cause excessive bleeding. The low number of red blood cells (anemia) can cause people with acute promyelocytic leukemia to have pale skin (pallor) or excessive tiredness (fatigue). In addition, affected individuals may heal slowly from injuries or have frequent infections due to the loss of normal white blood cells that fight infection. Furthermore, the leukemic cells can spread to the bones and joints, which may cause pain in those areas. Other general signs and symptoms may occur as well, such as fever, loss of appetite, and weight loss. Acute promyelocytic leukemia is most often diagnosed around age 40, although it can be diagnosed at any age.

MalaCards based summary : Acute Promyelocytic Leukemia, also known as acute myeloblastic leukemia type 3, is related to leukemia, acute myeloid and leukemia, chronic myeloid. An important gene associated with Acute Promyelocytic Leukemia is NUMA1 (Nuclear Mitotic Apparatus Protein 1), and among its related pathways/superpathways are Endometrial cancer and Pathways in cancer. The drugs Cyclophosphamide and Thiotepa have been mentioned in the context of this disorder. Affiliated tissues include myeloid, bone and bone marrow, and related phenotypes are muscle weakness and fatigue

Disease Ontology : 12 An acute myeloid leukemia characterized by accumulation of promyelocytes in the bone marrow and by a translocation between chromosomes 15 and 17.

NIH Rare Diseases : 52 Acute promyelocytic leukemia (APL) is an aggressive type of acute myeloid leukemia in which there are too many immature blood-forming cells (promyelocytes) in the blood and bone marrow. This build up of promyelocytes leads to a shortage of normal white and red blood cells and platelets in the body. The signs and symptoms of APL include an increased risk to both bleed and form blood clots. Individuals may also experience excessive tiredness, pain in affected areas, loss of appetite, and weight loss. APL usually occurs in middle-aged adults, but can be diagnosed at any age. It is caused by a mutation that is acquired over a person's lifetime, usually involving a translocation between chromosomes 15 and 17 . Treatment may include the use of all-trans retinoic acid (ATRA) and arsenic trioxide or anthracycline-based chemotherapy .

OMIM : 56 Acute promyelocytic leukemia (APL) is associated with 2 cardinal features: a granulocytic differentiation block and reciprocal and balanced translocations that always involve rearrangement of the RARA gene (180240). The most frequent translocation is t(15,17)(q21;q22), which fuses the RARA gene with the PML gene (102578) and represents more than 98% of APL (Vitoux et al., 2007). (612376)

Wikipedia : 74 Acute myeloid leukemia (AML) is a cancer of the myeloid line of blood cells, characterized by the rapid... more...

Related Diseases for Acute Promyelocytic Leukemia

Diseases related to Acute Promyelocytic Leukemia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 434)
# Related Disease Score Top Affiliating Genes
1 leukemia, acute myeloid 33.5 ZBTB16 STAT5B STAT3 RARA PML NPM1
2 leukemia, chronic myeloid 31.7 STAT5B STAT3 RARA PML NPM1 MIR223
3 myelofibrosis 31.6 STAT5B STAT3 NPM1 MIR223
4 myeloproliferative neoplasm 31.3 STAT5B STAT3 MIR126 FIP1L1
5 chronic leukemia 31.2 STAT5B STAT3 FIP1L1
6 lymphoma, non-hodgkin, familial 31.1 ZBTB16 STAT3 NPM1 MIR15A MIR126
7 leukemia, acute lymphoblastic 31.0 STAT5B MIRLET7C MIR223 MIR210 MIR126
8 leukemia, chronic lymphocytic 30.9 STAT5B STAT3 MIR223 MIR16-1 MIR15A MIR126
9 hematologic cancer 30.7 STAT5B STAT3 RARA NPM1 MIR223 MIR16-1
10 collagen disease 30.3 MIRLET7D MIR223 MIR16-1
11 hypereosinophilic syndrome 30.2 STAT5B STAT3 FIP1L1
12 prostate cancer 29.8 STAT5B STAT3 NPM1 MIRLET7D MIRLET7C MIR223
13 atrichia with papular lesions 11.8
14 antiphospholipid syndrome 11.6
15 skeletal defects, genital hypoplasia, and mental retardation 11.4
16 sneddon syndrome 11.4
17 lipodystrophy, partial, acquired 11.4
18 leukemia 11.4
19 myeloid leukemia 11.0
20 disseminated intravascular coagulation 11.0
21 acute leukemia 10.9
22 large granular lymphocyte leukemia 10.9 STAT5B STAT3
23 alk-positive anaplastic large cell lymphoma 10.8 STAT3 NPM1
24 bone marrow cancer 10.8 STAT5B STAT3 NPM1 MIR126
25 pancytopenia 10.7
26 myelodysplastic syndrome 10.7
27 chromosomal triplication 10.7
28 neutropenia 10.7
29 lymphocytic leukemia 10.6
30 thrombocytopenia 10.6
31 sezary's disease 10.6 STAT5B STAT3 MIR223
32 intracranial hypertension, idiopathic 10.6
33 myeloid sarcoma 10.5
34 47,xyy 10.5
35 severe combined immunodeficiency 10.5
36 hypertriglyceridemia, familial 10.4
37 sarcoma 10.4
38 cheilitis 10.4
39 spindle cell sarcoma 10.4
40 polykaryocytosis inducer 10.4
41 purpura 10.4
42 neuropathy 10.4
43 bone marrow necrosis 10.4
44 pituitary adenoma 10.4 PRKAR1A MIR223 MIR16-1 MIR15A
45 pancreatic ductal adenocarcinoma 10.4 STAT3 MIR223 MIR210 MIR15A
46 bladder disease 10.4 NUMA1 MIR16-1 MIR15A MIR126
47 down syndrome 10.4
48 langerhans cell histiocytosis 10.4
49 deficiency anemia 10.4
50 thrombosis 10.4

Graphical network of the top 20 diseases related to Acute Promyelocytic Leukemia:



Diseases related to Acute Promyelocytic Leukemia

Symptoms & Phenotypes for Acute Promyelocytic Leukemia

Human phenotypes related to Acute Promyelocytic Leukemia:

58 31 (show all 38)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 muscle weakness 58 31 frequent (33%) Frequent (79-30%) HP:0001324
2 fatigue 58 31 frequent (33%) Frequent (79-30%) HP:0012378
3 fever 58 31 frequent (33%) Frequent (79-30%) HP:0001945
4 anemia 58 31 frequent (33%) Frequent (79-30%) HP:0001903
5 pancytopenia 58 31 frequent (33%) Frequent (79-30%) HP:0001876
6 weight loss 58 31 frequent (33%) Frequent (79-30%) HP:0001824
7 gingival bleeding 58 31 frequent (33%) Frequent (79-30%) HP:0000225
8 thrombocytopenia 58 31 frequent (33%) Frequent (79-30%) HP:0001873
9 anorexia 58 31 frequent (33%) Frequent (79-30%) HP:0002039
10 vertigo 58 31 frequent (33%) Frequent (79-30%) HP:0002321
11 epistaxis 58 31 frequent (33%) Frequent (79-30%) HP:0000421
12 bruising susceptibility 58 31 frequent (33%) Frequent (79-30%) HP:0000978
13 petechiae 58 31 frequent (33%) Frequent (79-30%) HP:0000967
14 leukopenia 58 31 frequent (33%) Frequent (79-30%) HP:0001882
15 exertional dyspnea 58 31 frequent (33%) Frequent (79-30%) HP:0002875
16 chronic infection 58 31 frequent (33%) Frequent (79-30%) HP:0031035
17 disseminated intravascular coagulation 58 31 frequent (33%) Frequent (79-30%) HP:0005521
18 bone marrow hypercellularity 58 31 frequent (33%) Frequent (79-30%) HP:0031020
19 ecchymosis 58 31 frequent (33%) Frequent (79-30%) HP:0031364
20 gingival overgrowth 58 31 occasional (7.5%) Occasional (29-5%) HP:0000212
21 abdominal pain 58 31 occasional (7.5%) Occasional (29-5%) HP:0002027
22 neutropenia 58 31 occasional (7.5%) Occasional (29-5%) HP:0001875
23 leukocytosis 58 31 occasional (7.5%) Occasional (29-5%) HP:0001974
24 bone pain 58 31 occasional (7.5%) Occasional (29-5%) HP:0002653
25 lymphadenopathy 58 31 occasional (7.5%) Occasional (29-5%) HP:0002716
26 oral cavity bleeding 58 31 occasional (7.5%) Occasional (29-5%) HP:0030140
27 hypofibrinogenemia 58 31 occasional (7.5%) Occasional (29-5%) HP:0011900
28 stomatitis 58 31 occasional (7.5%) Occasional (29-5%) HP:0010280
29 alcoholism 58 31 occasional (7.5%) Occasional (29-5%) HP:0030955
30 diffuse alveolar hemorrhage 58 31 occasional (7.5%) Occasional (29-5%) HP:0025420
31 productive cough 58 31 occasional (7.5%) Occasional (29-5%) HP:0031245
32 hematuria 58 31 very rare (1%) Very rare (<4-1%) HP:0000790
33 gangrene 58 31 very rare (1%) Very rare (<4-1%) HP:0100758
34 metrorrhagia 58 31 very rare (1%) Very rare (<4-1%) HP:0100608
35 abnormal bleeding 58 Frequent (79-30%)
36 purpura 58 Frequent (79-30%)
37 acute promyelocytic leukemia 31 HP:0004836
38 abnormal granulocytopoietic cell morphology 31 HP:0012135

Clinical features from OMIM:

612376

MGI Mouse Phenotypes related to Acute Promyelocytic Leukemia:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 liver/biliary system MP:0005370 9.5 IRF2BP2 NPM1 PRKAR1A RARA STAT3 STAT5B
2 neoplasm MP:0002006 9.1 NPM1 PML PRKAR1A RARA STAT3 ZBTB16

Drugs & Therapeutics for Acute Promyelocytic Leukemia

Drugs for Acute Promyelocytic Leukemia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 214)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Cyclophosphamide Approved, Investigational Phase 4 50-18-0, 6055-19-2 2907
2
Thiotepa Approved, Investigational Phase 4 52-24-4 5453
3
Daunorubicin Approved Phase 4 20830-81-3 30323
4
Thioguanine Approved Phase 3 154-42-7 2723601
5
Methotrexate Approved Phase 3 1959-05-2, 59-05-2 126941
6
leucovorin Approved Phase 3 58-05-9 6006 143
7
Etoposide Approved Phase 3 33419-42-0 36462
8
Miconazole Approved, Investigational, Vet_approved Phase 3 22916-47-8 4189
9
Ribavirin Approved Phase 3 36791-04-5 37542
10
Palivizumab Approved, Investigational Phase 3 188039-54-5
11
Captopril Approved Phase 3 62571-86-2 44093
12
Fluconazole Approved, Investigational Phase 3 86386-73-4 3365
13
Itraconazole Approved, Investigational Phase 3 84625-61-6 55283
14
Hydrocortisone acetate Approved, Vet_approved Phase 3 50-03-3
15
Hydrocortisone Approved, Vet_approved Phase 3 50-23-7 5754
16
Amsacrine Approved, Investigational Phase 3 51264-14-3 2179
17
Amphotericin B Approved, Investigational Phase 3 1397-89-3 14956 5280965
18
Cytarabine Approved, Experimental, Investigational Phase 3 147-94-4, 65-46-3 6253
19
Azacitidine Approved, Investigational Phase 3 320-67-2 9444
20
Idarubicin Approved Phase 3 58957-92-9 42890
21
Mitoxantrone Approved, Investigational Phase 3 65271-80-9 4212
22
tannic acid Approved Phase 3 1401-55-4
23
Hydroxyurea Approved Phase 3 127-07-1 3657
24
Benzocaine Approved, Investigational Phase 3 1994-09-7, 94-09-7 2337
25
Lenograstim Approved, Investigational Phase 3 135968-09-1
26
Fludarabine Approved Phase 3 21679-14-1, 75607-67-9 30751
27
Cladribine Approved, Investigational Phase 3 4291-63-8 20279
28
Mercaptopurine Approved Phase 3 50-44-2 667490
29
Ichthammol Approved Phase 3 8029-68-3
30
Histamine Approved, Investigational Phase 3 51-45-6 774
31
Cyproheptadine Approved Phase 3 129-03-3 2913
32
Folic acid Approved, Nutraceutical, Vet_approved Phase 3 59-30-3 6037
33
Vitamin A Approved, Nutraceutical, Vet_approved Phase 3 68-26-8, 11103-57-4, 22737-96-8 445354 9904001
34 Vaccines Phase 3
35 Antibodies Phase 3
36 Immunoglobulins Phase 3
37 Vitamin B Complex Phase 3
38 Folic Acid Antagonists Phase 3
39 Vitamin B9 Phase 3
40 Antirheumatic Agents Phase 3
41 Folate Phase 3
42 Antibodies, Monoclonal Phase 3
43 Alkylating Agents Phase 3
44 Etoposide phosphate Phase 3
45 Antifungal Agents Phase 3
46 Steroid Synthesis Inhibitors Phase 3
47 Flt3 ligand protein Phase 3
48 Radiation-Protective Agents Phase 3
49 Cytochrome P-450 CYP3A Inhibitors Phase 3
50 Cytochrome P-450 Enzyme Inhibitors Phase 3

Interventional clinical trials:

(show top 50) (show all 184)
# Name Status NCT ID Phase Drugs
1 AIDA2000 - Risk-Adapted Therapy for Patients With Acute Promyelocytic Leukemia(APL) Unknown status NCT00180128 Phase 4 all-trans retinoid acid;idarubicin;mitoxantrone;daunorubicin;cytarabine
2 Treatment of Relapsed Acute Promyelocytic Leukemia With Arsenic Trioxide (Phase IV Study) Unknown status NCT00196768 Phase 4 Arsenic trioxide;Trisenox
3 Treatment of Newly Diagnosed Patients With Acute Promyelocytic Leukemia (PETHEMA LPA 2005): Remission Induction With ATRA + Idarubicin. Risk-adapted Consolidation With ATRA and Anthracycline-based Chemotherapy (Idarubicin/Mitoxantrone) With Addition of Ara-C for High-risk Patients. Maintenance Therapy With ATRA + Low Dose Chemotherapy (Methotrexate + Mercaptopurine). Completed NCT00408278 Phase 4 ATRA;Idarubicina;Mitoxantrone;ARA-C
4 Treatment of Acute Promyelocytic Leukemia: Remission Induction With ATRA + Idarubicin (AIDA) Risk Adapted Intensity of Consolidation and Addition of ATRA Maintenance With ATRA + Methotrexate + Mercaptopurine Salvage Therapy for Molecular and Haematological Relapses Completed NCT00465933 Phase 4 AIDA
5 APL-R2007: Treatment of Relapsed Promyelocytic Leukemia With Arsenic Trioxide (ATO) Completed NCT00504764 Phase 4 Arsenic Trioxide;ATRA
6 Evaluation of Allogeneic Marrow Transplants Depleted of T-Cells by CD34+ Selection in Patients Undergoing Transplantation With an Unrelated Matched or 1 Antigen Mismatched Donor or a 1 Antigen Mismatched Related Donor Completed NCT00003398 Phase 4 cyclophosphamide;thiotepa
7 A Multicenter and Randomized Prospective Study for Improving the Outcome of Childhood Acute Promyeloid Leukemia Recruiting NCT02200978 Phase 4 ATO;RIF;ATRA;mitoxantrone;Ara-C;MTX;6MP
8 Combined Retinoic Acid,Arsenic Trioxide and Chemotherapy for Newly-diagnosed Acute Promyelocytic Leukemia: Chinese National Multi-center Randomized Study Active, not recruiting NCT01987297 Phase 4 ATRA+Arsenic;ATRA+Chemo
9 Molecular Remission With Arsenic Trioxide in Acute Promyelocytic Leukemia: Indian APL Study Group - IAPLSG Unknown status NCT00517712 Phase 2, Phase 3 Single agent arsenic trioxide
10 Treatment Study for Children and Adolescents With Acute Promyelocitic Leukemia Unknown status NCT01226303 Phase 3 ATRA;ATRA + IDA
11 A Randomized Trial Assessing the Role of Arsenic Trioxide and/or ATRA During Consolidation Course in Newly Diagnosed Acute Promyelocytic Leukemia (APL) Unknown status NCT00378365 Phase 3
12 INDUCTION WITH ALL-TRANS RETINOIC ACID IN COMBINATION WITH IDARUBICIN AND INTENSIVE CONSOLIDATION FOLLOWED BY BONE MARROW TRANSPLANTATION OR A RANDOMIZED MAINTENANCE TREATMENT DEPENDING UPON THE AMOUNT OF MINIMAL RESIDUAL DISEASE IN ACUTE PROMYELOCYTIC LEUKEMIA Unknown status NCT00002701 Phase 3 busulfan;cyclophosphamide;cytarabine;etoposide;idarubicin;mercaptopurine;methotrexate;mitoxantrone hydrochloride;thioguanine;tretinoin
13 A Phase 3, Randomized, Double-Blind, Multicenter Study of Proteinase 3 PR1 Peptide Mixed With Montanide ISA-51 VG Adjuvant and Administered With GM-CSF in Elderly Patients With AML in First Complete Remission or Adults in Second Complete Remission: A Pivotal Study Unknown status NCT00454168 Phase 3
14 Combination of Ibrutinib and As2O3 in the Treatment of CLL Unknown status NCT02757040 Phase 3 Ibrutinib combined with As2O3;ibrutinib
15 ACUTE MYELOID LEUKAEMIA TRIAL 12 Unknown status NCT00002658 Phase 3 amsacrine;cyclophosphamide;cytarabine;daunorubicin hydrochloride;etoposide;idarubicin;mitoxantrone hydrochloride;thioguanine;tretinoin
16 Comparison of Ara-c 12 gm/m2 vs 18 gm/m2 Per Cycle for 3 Cycles Each as Consolidation in AML ; An Open Label Randomized Non-inferiority Study Unknown status NCT01615757 Phase 3 Ara-c;Ara-c
17 A Randomized Study of Two Doses Gemtuzumab Ozogamicin vs. A Two-year Maintenance With Atra Plus Chemotherapy as Post-consolidation Treatment for Intermediate and High-risk Adult Patients With Acute Promyelocytic Leukemia (Apl) Completed NCT00962767 Phase 3 gemtuzumab ozogamicin;ATRA plus 6-MP and MTX
18 A Randomized Trial Assessing the Roles of AraC in Newly Diagnosed Acute Promyelocytic Leukemia (APL) Completed NCT00591526 Phase 3 Arac
19 Phase III Randomized Study of Concurrent Tretinoin and Chemotherapy With or Without Arsenic Trioxide (AS2O3) (NSC # 706363) as Initial Consolidation Therapy Followed by Maintenance Therapy With Intermittent Tretinoin Versus Intermittent Tretinoin Plus Mercaptopurine and Methotrexate for Patients With Untreated Acute Promyelocytic Leukemia Completed NCT00003934 Phase 3 tretinoin;daunorubicin hydrochloride;cytarabine;mercaptopurine;methotrexate;arsenic trioxide
20 S0521, A Randomized Trial of Maintenance Versus Observation for Patients With Previously Untreated Low and Intermediate Risk Acute Promyelocytic Leukemia (APL), Phase III Completed NCT00492856 Phase 3 mercaptopurine;methotrexate;tretinoin
21 Risk Adapted Treatment of Newly Diagnosed Childhood Acute Promyelocytic Leukemia (APL) Using Arsenic Trioxide (Trisenox® IND# 103, 331) During Consolidation Completed NCT00866918 Phase 3 arsenic trioxide;mitoxantrone hydrochloride;idarubicin;tretinoin;cytarabine;mercaptopurine tablet;methotrexate
22 Assessment of the Optimal Timing of Chemotherapy With or After ATRA and the Role of Maintenance Completed NCT00599937 Phase 3 ATRA;ATRA and or Chemo as maintenance
23 A Phase III Study of Flt3 Ligand (Flt3L) Therapy in Acute Myeloid Leukemia (AML) Patients in Remission Completed NCT00006223 Phase 3
24 A Randomized Double-Blind Placebo-Controlled Phase III Study To Evaluate The Safety And Efficacy Of Palivizumab Combined With Aerosolized Ribavirin Compared To Ribavirin Alone To Treat RSV Pneumonia In Patients With Bone Marrow Transplants (BMT) Completed NCT00014391 Phase 3 ribavirin
25 Phase III Study of Captopril in Patients Undergoing Autologous Bone Marrow/Stem Cell Transplantation Completed NCT00004230 Phase 3 captopril;cyclophosphamide
26 A Randomized, Comparative Study of Itraconazole Versus Fluconazole for Prevention of Aspergillus Infections in Peripheral Blood Stem Cell and Marrow Transplant Recipients Completed NCT00003883 Phase 3 fluconazole;itraconazole
27 Medical Research Council Working Party on Leukaemia in Childhood Acute Myeloid Leukaemia Trial 12 Completed NCT00003436 Phase 3 amsacrine;asparaginase;cytarabine;daunorubicin hydrochloride;etoposide;methotrexate;mitoxantrone hydrochloride;therapeutic hydrocortisone
28 A Strategic Study to Determine the Optimal Moment to Initiate Systemic Antifungal Therapy With Ambisome in Granulocytopenic Cancer Patients With Unexplained Fever Refractory to Empirical Antibacterials Completed NCT00003938 Phase 3 liposomal amphotericin B
29 Treatment of Non-high-risk Acute Promyelocytic Leukemia With Realgar-Indigo Naturalis Formula (RIF) and All-trans Retinoid Acid (ATRA) Recruiting NCT02899169 Phase 3 Realgar-Indigo naturalis formula;all-trans retinoic acid;Arsenic trioxide;Hydroxyurea
30 A Phase III, Double-Blind, Placebo-Controlled, Multicenter, Randomized Study Of Pracinostat In Combination With Azacitidine In Patients ≥18 Years With Newly Diagnosed Acute Myeloid Leukemia Unfit For Standard Induction Chemotherapy Recruiting NCT03151408 Phase 3 Pracinostat;Placebos;Azacitidine
31 A PALG Prospective Multicenter Clinical Trial to Compare the Efficacy of Two Standard Induction Therapies (DA-90 vs DAC) and Two Standard Salvage Regimens (FLAG-IDA vs CLAG-M) in AML Patients ≤ 60 Years Old Recruiting NCT03257241 Phase 3 A arm (DA-90);B arm (DAC);A arm (CLAG-M);B arm (FLAG-IDA)
32 A Randomized Phase III Study to Compare Arsenic Trioxide (ATO) Combined to ATRA and Idarubicin Versus Standard ATRA and Anthracyclines-based Chemotherapy (AIDA Regimen) for Patients With Newly Diagnosed, High-risk Acute Promyelocytic Leukemia Active, not recruiting NCT02688140 Phase 3 Arsenic trioxide;Idarubicin;Cytarabine;Tretinoin;Mitoxantrone;Mercaptopurine;Methotrexate
33 A Phase III Study for Patients With Newly Diagnosed Acute Promyelocytic Leukemia (APL) Using Arsenic Trioxide and All-Trans Retinoic Acid Active, not recruiting NCT02339740 Phase 3 Arsenic Trioxide;Cytarabine;Dexamethasone;Idarubicin;Mitoxantrone Hydrochloride;Tretinoin
34 A Randomised Phase III Study to Compare Arsenic Trioxide (ATO) Combined to ATRA Versus Standard ATRA and Anthracycline-Based Chemotherapy (AIDA Regimen) for Newly Diagnosed, Non High-Risk Acute Promyelocytic Leukemia Active, not recruiting NCT00482833 Phase 3 arsenic trioxide;idarubicin;mercaptopurine;methotrexate;all-trans retinoic acid;all-trans retinoic acid (ATRA)
35 Implement Randomized, Controlled, International Multi-center Clinical Trial of Compound Realgar-Indigo Naturalis Formula Plus Retinoic Acid for Non-high-risk Acute Promyelocytic Leukaemia Not yet recruiting NCT04175587 Phase 3 Compound Realgar-Indigo Naturalis Formula Plus Retinoic Acid
36 Prevention of Cancer/Treatment-Related Weight Loss in Children at High Nutritional Risk Terminated NCT01132547 Phase 3 cyproheptadine hydrochloride
37 Phase II Study of NRX 195183 Therapy for Patients With Relapsed or Refractory Acute Promyelocytic Leukemia Unknown status NCT00675870 Phase 2 NRX 195183 Soft Gelatin Capsule
38 Phase II Study to Evaluate the Role of Bortezomib in the Management of Relapsed Acute Promyelocytic Leukemia Unknown status NCT01950611 Phase 2 Bortezomib
39 Phase I/II Pilot Trial of ATRA (Tretinoin) and TCP (Tranylcypromine) in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) and no Intensive Treatment is Possible Unknown status NCT02261779 Phase 1, Phase 2 Tranylcypromine;Tretinoin
40 Fludarabine and Cytarabine as Continuous Infusion Plus Idarubicin With Granulocyte-Colony Stimulating Factor (G-CSF) Priming for Patients Younger Than 60 Years With Resistant Acute Myeloid Leukemia Unknown status NCT00559221 Phase 2 FLAG+IDA
41 Fludarabine and Cytarabine as Continuous Infusion Plus G-CSF Priming for Elderly Patients With Resistant AML Unknown status NCT00529880 Phase 2 Fludarabine , cytarabine
42 A Multiinstitutional Trial To Evaluate The Prophylactic Use Of NASA-Developed Light Emitting Diodes For The Prevention Of Oral Mucositis In Bone Marrow Transplant Patients Unknown status NCT00036712 Phase 2
43 A Phase I/II Trial of Infusional Arsenic Trioxide for Relapsed Acute Promyelocytic Leukemia Completed NCT00008697 Phase 1, Phase 2 arsenic trioxide
44 A Phase II Study of Oral Tamibarotene in Acute Promyelocytic Leukemia Patients Who Have Received Prior Therapy With ATRA and Arsenic Trioxide (STAR-1) Completed NCT00520208 Phase 2 Tamibarotene
45 A Pilot Study of Arsenic Trioxide-Based Consolidation Therapy for the Primary Treatment of Acute Promyelocytic Leukemia Completed NCT00276601 Phase 2 arsenic trioxide;cytarabine;daunorubicin hydrochloride;mercaptopurine;methotrexate;tretinoin
46 Phase II Study Of Combined Modality Postremission Therapy As Determined By Molecular Response (Adaptive Regulation) In The Treatment Of Acute Promyelocytic Leukemia (APL) Completed NCT00016159 Phase 2 arsenic trioxide;idarubicin;tretinoin
47 PHASE II TRIAL OF POST-REMISSION THERAPY WITH HuM195 AND CYTOTOXIC CHEMOTHERAPY FOR ACUTE PROMYELOCYTIC LEUKEMIA Completed NCT00002609 Phase 2 cytarabine;idarubicin
48 S0535, A Phase II Study of ATRA, Arsenic Trioxide and Gemtuzumab Ozogamicin in Patients With Previously Untreated High-Risk Acute Promyelocytic Leukemia Completed NCT00551460 Phase 2 arsenic trioxide;gemtuzumab ozogamicin;mercaptopurine;methotrexate;tretinoin
49 Treatment of Acute Promyelocytic Leukemia (APL) With All-Trans Retinoic Acid, and Arsenic +/- Idarubicin Completed NCT00413166 Phase 2 All-Trans Retinoic Acid (ATRA);Arsenic Trioxide (ATO);Idarubicin;Gemtuzumab Ozogamicin
50 A Phase 2 Study of Depsipeptide in Patients With Relapsed or Refractory AML Completed NCT00062075 Phase 2 romidepsin

Search NIH Clinical Center for Acute Promyelocytic Leukemia

Inferred drug relations via UMLS 71 / NDF-RT 50 :


Arsenic
arsenic trioxide
Tretinoin
TRETINOIN PWDR

Cochrane evidence based reviews: leukemia, promyelocytic, acute

Genetic Tests for Acute Promyelocytic Leukemia

Genetic tests related to Acute Promyelocytic Leukemia:

# Genetic test Affiliating Genes
1 Acute Promyelocytic Leukemia 29 NUMA1 RARA

Anatomical Context for Acute Promyelocytic Leukemia

MalaCards organs/tissues related to Acute Promyelocytic Leukemia:

40
Myeloid, Bone, Bone Marrow, T Cells, Lung, Skin, Liver

Publications for Acute Promyelocytic Leukemia

Articles related to Acute Promyelocytic Leukemia:

(show top 50) (show all 6170)
# Title Authors PMID Year
1
A novel NUP98/RARG gene fusion in acute myeloid leukemia resembling acute promyelocytic leukemia. 61 56
20935257 2011
2
The PRKAR1A gene is fused to RARA in a new variant acute promyelocytic leukemia. 61 56
17712046 2007
3
Acute promyelocytic leukemia: new issues on pathogenesis and treatment response. 61 56
17468032 2007
4
Translocations of the RARalpha gene in acute promyelocytic leukemia. 61 56
11704847 2001
5
Oncogenes and tumor suppressors in the molecular pathogenesis of acute promyelocytic leukemia. 61 56
11257111 2001
6
Genetic diagnosis and molecular monitoring in the management of acute promyelocytic leukemia. 61 56
10381493 1999
7
Interstitial insertion of retinoic acid receptor-alpha gene in acute promyelocytic leukemia with normal chromosomes 15 and 17. 61 56
8180390 1994
8
Rearrangements of the retinoic acid receptor alpha and promyelocytic leukemia zinc finger genes resulting from t(11;17)(q23;q21) in a patient with acute promyelocytic leukemia. 61 56
8387545 1993
9
Molecular analysis of acute promyelocytic leukemia breakpoint cluster region on chromosome 17. 61 56
2218500 1990
10
Cloning and characterization of the t(15;17) translocation breakpoint region in acute promyelocytic leukemia. 61 56
2278973 1990
11
Transcriptional repression of microRNA genes by PML-RARA increases expression of key cancer proteins in acute promyelocytic leukemia. 61 46
18941112 2009
12
MicroRNA gene expression during retinoic acid-induced differentiation of human acute promyelocytic leukemia. 61 46
17260024 2007
13
Emerging role for microRNAs in acute promyelocytic leukemia. 61 46
17217039 2007
14
Fusion of retinoic acid receptor alpha to NuMA, the nuclear mitotic apparatus protein, by a variant translocation in acute promyelocytic leukaemia. 56
9288109 1997
15
The t(15;17) translocation of acute promyelocytic leukaemia fuses the retinoic acid receptor alpha gene to a novel transcribed locus. 56
2170850 1990
16
Interstitial insertion of varying amounts of ABL-containing genetic material into chromosome 22 in Ph-negative CML. 56
2164119 1990
17
Prognostic significance of FLT3 internal tandem duplication and tyrosine kinase domain mutations in acute promyelocytic leukemia: a systematic review. 54 61
20096459 2010
18
Long FLT3 internal tandem duplications and reduced PML-RARα expression at diagnosis characterize a high-risk subgroup of acute promyelocytic leukemia patients. 54 61
20133893 2010
19
Promyelocytic leukemia protein controls cell migration in response to hydrogen peroxide and insulin-like growth factor-1. 54 61
20100838 2010
20
t(X;17) as the sole karyotypic anomaly in a case of M(3r) subtype of acute promyelocytic leukemia without RARalpha rearrangement. 54 61
19477513 2010
21
PML/RARalpha fusion protein transactivates the tissue factor promoter through a GAGC-containing element without direct DNA association. 54 61
20133705 2010
22
Mobilization of PML/RARalpha negative peripheral blood stem cells with a combination of G-CSF and CXCR4 blockade in relapsed acute promyelocytic leukemia pre-treated with arsenic trioxide. 54 61
19815840 2010
23
Evidence for direct involvement of epirubicin in the formation of chromosomal translocations in t(15;17) therapy-related acute promyelocytic leukemia. 54 61
19884644 2010
24
miR-128b is a potent glucocorticoid sensitizer in MLL-AF4 acute lymphocytic leukemia cells and exerts cooperative effects with miR-221. 46
19749093 2009
25
The cytotoxic effects of gemtuzumab ozogamicin (mylotarg) in combination with conventional antileukemic agents by isobologram analysis in vitro. 54 61
20032408 2009
26
[Apoptosis of MR2 cells induced by Tanshinone II A combined with arsenic trioxide]. 54 61
19950589 2009
27
Arsenic trioxide downregulates the expression of annexin II in bone marrow cells from patients with acute myelogenous leukemia. 54 61
19781379 2009
28
A label-free quantitative proteomics strategy to identify E3 ubiquitin ligase substrates targeted to proteasome degradation. 54 61
19376791 2009
29
Role of SUMO in RNF4-mediated promyelocytic leukemia protein (PML) degradation: sumoylation of PML and phospho-switch control of its SUMO binding domain dissected in living cells. 54 61
19380586 2009
30
All-trans retinoic acid induces Thrombospondin-1 expression in acute promyelocytic leukemia cells though down-regulation of its transcription repressor, c-MYC oncoprotein. 54 61
19324018 2009
31
Simultaneous occurrence of MLL and RARA rearrangements in a pediatric acute lymphoblastic leukemia patient. 54 61
19142993 2009
32
Inhibition of class I phosphoinositide 3-kinase activity impairs proliferation and triggers apoptosis in acute promyelocytic leukemia without affecting atra-induced differentiation. 54 61
19176369 2009
33
[Molecular diagnosis of and molecular targeting therapy for leukemia]. 54 61
19317219 2009
34
Acute promyelocytic leukemia with insertion of PML exon 7a and partial deletion of exon 3 of RARA: a novel variant transcript related to aggressive course and not detected with real-time polymerase chain reaction analysis. 54 61
19100514 2009
35
A bcr3/short form PML-RARalpha transcript in an acute promyelocytic leukemia resulted from a derivative chromosome 17 due to submicroscopic insertion of the PML gene into the RARalpha locus. 54 61
19095567 2009
36
PML nuclear bodies in the pathogenesis of acute promyelocytic leukemia: active players or innocent bystanders? 54 61
19273155 2009
37
PML nuclear bodies as sites of epigenetic regulation. 54 61
19273133 2009
38
Identification of PML/RARalpha fusion gene transcripts that showed no t(15;17) with conventional karyotyping and fluorescent in situ hybridization. 54 61
19224461 2009
39
Acute promyelocytic leukemia with t(15;17): frequency of additional clonal chromosome abnormalities and FLT3 mutations. 54 61
19052993 2008
40
ASB2 targets filamins A and B to proteasomal degradation. 54 61
18799729 2008
41
[Prevalence and clinical significance of FLT3 mutations in acute promyelocytic leukemia]. 54 61
19176014 2008
42
Involvement of PML nuclear bodies in CBP degradation through the ubiquitin-proteasome pathway. 54 61
19011377 2008
43
MicroRNA-126 regulates HOXA9 by binding to the homeobox. 46
18474618 2008
44
A new complex translocation t(5;17;15)(q11;q21;q22) in acute promyelocytic leukemia. 54 61
18558288 2008
45
Arsenic trioxide augments Chk2/p53-mediated apoptosis by inhibiting oncogenic Wip1 phosphatase. 54 61
18482988 2008
46
Cyclin-dependent kinase antagonizes promyelocytic leukemia zinc-finger through phosphorylation. 54 61
18246121 2008
47
UBE1L represses PML/RAR{alpha} by targeting the PML domain for ISG15ylation. 54 61
18413804 2008
48
Hypercoagulability and tissue factor gene upregulation in hematologic malignancies. 54 61
18645927 2008
49
Diagnostic challenges related to myeloid/natural killer cells, a variant of myeloblasts. 54 61
18787634 2008
50
Adhesion molecules and Differentiation Syndrome: phenotypic and functional analysis of the effect of ATRA, As2O3, phenylbutyrate, and G-CSF in acute promyelocytic leukemia. 54 61
18055984 2007

Variations for Acute Promyelocytic Leukemia

ClinVar genetic disease variations for Acute Promyelocytic Leukemia:

6 ‎‎
# Gene Name Type Significance ClinVarId dbSNP ID GRCh37 Pos GRCh38 Pos
1 TMEM127 NM_017849.3(TMEM127):c.31G>T (p.Gly11Cys)SNV Uncertain significance 577335 rs992633976 2:96931089-96931089 2:96265351-96265351

Copy number variations for Acute Promyelocytic Leukemia from CNVD:

7 (show all 28)
# CNVD ID Chromosome Start End Type Gene Symbol CNVD Disease
1 17351 1 142487224 245120412 Gain Acute promyelocytic leukemia
2 29128 1 227843862 227867765 Deletion EGLN1 Acute promyelocytic leukemia
3 44777 10 62496958 68046104 Deletion Acute promyelocytic leukemia
4 71119 12 6755671 29248257 Deletion Acute promyelocytic leukemia
5 78273 13 49630676 50510777 Deletion DLEU7 Acute promyelocytic leukemia
6 78274 13 49630676 50510777 Deletion FAM10A4 Acute promyelocytic leukemia
7 78275 13 49630676 50510777 Deletion GUCY1B2 Acute promyelocytic leukemia
8 78767 13 56784440 114051465 Duplication Acute promyelocytic leukemia
9 93669 15 57244668 100182183 Duplication Acute promyelocytic leukemia
10 94970 15 72224840 100192115 Duplication Acute promyelocytic leukemia
11 108134 17 18901 21459693 Deletion Acute promyelocytic leukemia
12 108602 17 21491135 35542587 Duplication Acute promyelocytic leukemia
13 123386 18 7192739 7657575 Duplication PTPRM Acute promyelocytic leukemia
14 157044 21 1 48129895 Tri Acute promyelocytic leukemia
15 158722 21 36234195 46924583 Duplication Acute promyelocytic leukemia
16 181722 4 125190507 126521903 Deletion Acute promyelocytic leukemia
17 214094 6 5545437 8054930 Deletion Acute promyelocytic leukemia
18 220370 7 137795618 137920872 Translate TIF1 Acute promyelocytic leukemia
19 226739 7 61522282 158554645 Deletion Acute promyelocytic leukemia
20 228938 7 85414972 86445002 Deletion DMTF1 Acute promyelocytic leukemia
21 228939 7 85414972 86445002 Deletion GRM3 Acute promyelocytic leukemia
22 228940 7 85414972 86445002 Deletion KIAA1324L Acute promyelocytic leukemia
23 230737 8 1 146364022 Tri Acute promyelocytic leukemia
24 233093 8 122607785 132092760 Duplication Acute promyelocytic leukemia
25 254363 9 64207745 111479523 Deletion Acute promyelocytic leukemia
26 256567 9 94435025 94710006 Duplication C9orf3 Acute promyelocytic leukemia
27 256568 9 94435025 94710006 Duplication FBP1 Acute promyelocytic leukemia
28 256569 9 94435025 94710006 Duplication FBP2 Acute promyelocytic leukemia

Expression for Acute Promyelocytic Leukemia

Search GEO for disease gene expression data for Acute Promyelocytic Leukemia.

Pathways for Acute Promyelocytic Leukemia

GO Terms for Acute Promyelocytic Leukemia

Cellular components related to Acute Promyelocytic Leukemia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 nucleoplasm GO:0005654 9.36 TBL1XR1 STAT5B STAT3 RARA PML NUMA1
2 spindle pole centrosome GO:0031616 8.96 NUMA1 NPM1

Biological processes related to Acute Promyelocytic Leukemia according to GeneCards Suite gene sharing:

(show all 15)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of transcription, DNA-templated GO:0045893 9.93 ZBTB16 TBL1XR1 STAT3 RARA NPM1
2 negative regulation of transcription, DNA-templated GO:0045892 9.89 ZBTB16 TBL1XR1 RARA PML BCOR
3 positive regulation of transcription by RNA polymerase II GO:0045944 9.86 ZBTB16 TBL1XR1 STAT5B STAT3 RARA NPM1
4 negative regulation of angiogenesis GO:0016525 9.72 PML MIR16-1 MIR15A
5 response to estradiol GO:0032355 9.69 STAT5B STAT3 RARA
6 negative regulation of inflammatory response GO:0050728 9.67 MIR223 MIR16-1 MIR15A MIR126
7 response to cytokine GO:0034097 9.58 STAT3 RARA PML
8 retinoic acid receptor signaling pathway GO:0048384 9.52 RARA PML
9 JAK-STAT cascade involved in growth hormone signaling pathway GO:0060397 9.48 STAT5B STAT3
10 interleukin-15-mediated signaling pathway GO:0035723 9.46 STAT5B STAT3
11 miRNA mediated inhibition of translation GO:0035278 9.46 STAT3 MIR210 MIR16-1 MIR15A
12 interleukin-9-mediated signaling pathway GO:0038113 9.43 STAT5B STAT3
13 gene silencing by miRNA GO:0035195 9.43 MIRLET7C MIR223 MIR210 MIR16-1 MIR15A MIR126
14 negative regulation of cell chemotaxis to fibroblast growth factor GO:1904848 9.32 MIR16-1 MIR15A
15 negative regulation of cell proliferation GO:0008285 9.17 ZBTB16 STAT3 RARA PML NPM1 MIR16-1

Molecular functions related to Acute Promyelocytic Leukemia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein domain specific binding GO:0019904 9.46 ZBTB16 RARA PRKAR1A NUMA1
2 glucocorticoid receptor binding GO:0035259 9.26 STAT5B STAT3
3 transcription regulatory region DNA binding GO:0044212 9.26 TBL1XR1 STAT3 RARA BCOR
4 mRNA binding involved in posttranscriptional gene silencing GO:1903231 9.1 MIRLET7C MIR223 MIR210 MIR16-1 MIR15A MIR126

Sources for Acute Promyelocytic Leukemia

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....